by editors@theworld.org (Joshua Coe) on (#74CTJ)
The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent - held by Danish pharmaceutical giant Novo Nordisk - opens the door to affordable generic versions in the country. The World's Host Carolyn Beeler learns more about the potential impact from Dr. Rahul Baxi, a diabetologist in Mumbai.